Hematological Parameters and Hematopoietic Progenitor Numbers at 20 Weeks After Completion of a Six-Cycle Administration of Cytotoxic Agents
| Treatment . | WBC (×106/mL) . | P Value-150 . | BMC (×106/HL) . | P Value-150 . | CFU-S/HL . | P Value-150 . |
|---|---|---|---|---|---|---|
| Saline | 10.7 ± 0.5 (5) | — | 51.0 ± 3.5 (5) | — | 6,109 ± 440 (15) | — |
| VP-16 + cisplatinum | NA | NA | 7,588 ± 1,515 (6) | .38 | ||
| Cyclophosphamide | 9.9 ± 1.4 (5) | .63 | 47.3 ± 4.3 (5) | .51 | 6,132 ± 509 (13) | .97 |
| Carboplatinum | 8.7 ± 0.9 (5) | .10 | 40.6 ± 1.3 (5) | .03 | 4,523 ± 487 (8) | .03 |
| Chlorambucil | 9.1 ± 0.8 (5) | .14 | 45.0 ± 2.9 (5) | .21 | 5,063 ± 560 (8) | .16 |
| BCNU | NA | 33.9 ± 4.9 (3) | .02 | 4,475 ± 218 (10) | <.01 | |
| TBI | 7.0 ± 1.2 (5) | .03 | 46.4 ± 2.5 (5) | .31 | 1,905 ± 182 (16) | <.01 |
| Treatment . | WBC (×106/mL) . | P Value-150 . | BMC (×106/HL) . | P Value-150 . | CFU-S/HL . | P Value-150 . |
|---|---|---|---|---|---|---|
| Saline | 10.7 ± 0.5 (5) | — | 51.0 ± 3.5 (5) | — | 6,109 ± 440 (15) | — |
| VP-16 + cisplatinum | NA | NA | 7,588 ± 1,515 (6) | .38 | ||
| Cyclophosphamide | 9.9 ± 1.4 (5) | .63 | 47.3 ± 4.3 (5) | .51 | 6,132 ± 509 (13) | .97 |
| Carboplatinum | 8.7 ± 0.9 (5) | .10 | 40.6 ± 1.3 (5) | .03 | 4,523 ± 487 (8) | .03 |
| Chlorambucil | 9.1 ± 0.8 (5) | .14 | 45.0 ± 2.9 (5) | .21 | 5,063 ± 560 (8) | .16 |
| BCNU | NA | 33.9 ± 4.9 (3) | .02 | 4,475 ± 218 (10) | <.01 | |
| TBI | 7.0 ± 1.2 (5) | .03 | 46.4 ± 2.5 (5) | .31 | 1,905 ± 182 (16) | <.01 |
WBC and BMC; number is given in parentheses for individual mice from 1 to 3 separate experiments. CFU-S frequencies were determined from pooled marrow from 3 to 5 mice per experiment, the average frequency was calculated from 1 to 3 experiments; total number of CFU-S recipients is given in parentheses.
Abbreviations: BMC, bone marrow cellularity; NA, not available.
P value for comparison with saline.